Outcome of Board Meeting held on May 25, 2026
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics reported audited FY26 results with standalone PAT growing 24% to ₹1,026.75 million (EPS ₹31.69) and consolidated PAT rising 30.7% to ₹1,014.31 million (EPS ₹31.30). Consolidated revenue from operations increased 7.8% to ₹7,727.74 million. The board recommended a final dividend of ₹2 per share (40% of face value). Statutory auditors issued unmodified (clean) opinions. The auditors drew an emphasis of matter on income tax search proceedings resulting in a demand of ₹626.90 million, which the company is contesting. The board also recommended appointing Kirtane & Pandit LLP as new statutory auditors for FY27-31, replacing MSKA & Associates. Borrowings surged significantly from ₹185 million to ₹4,371 million due to ₹4,174 million debenture issuance.
The company delivered strong PAT growth above 25% on consolidated basis, which could be positive for the stock. However, the significant debt increase and ongoing tax disputes warrant monitoring. The auditor change and tax demand may create some investor concern in the short term.